Collaboration aims to treat hypertension in patients with high cardiovascular risk.
With the objective of development and commercialization of zilebesiran, an investigational RNA interface (RNAi) therapeutic, Roche has announced a partnership with Anyham. Currently in phase 2 of development, the finished product is expected to support patients with hypertension and high cardiovascular risks.
Under the collaboration, the organizations will work together to commercialize zilebesiran in the US, sharing costs and potential profits. Roche will maintain exclusive commercialization rights in other territories, with Alnylam receiving an upfront payment of $310 million.
“We are excited to work together with Alnylam and leverage our strong R&D capabilities, our leadership in cardiovascular diagnostics and our global commercial footprint to further develop and provide this promising therapy with best-in-disease potential to patients,” said Teresa Graham, CEO Roche Pharma. “Throughout our history, we have redefined the standard of care across various disease areas. Together with a strong partner like Alnylam, we are looking forward to making a significant impact for patients living with hypertension at high cardiovascular risk and potentially other cardiovascular indications.”
Reference: Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk. GlobeNewswire. July 24, 2023. Accessed July 26, 2023. https://www.globenewswire.com/news-release/2023/07/24/2709218/0/en/Roche-enters-partnership-with-Alnylam-to-co-develop-and-co-commercialise-RNAi-therapeutic-zilebesiran-to-treat-hypertension-in-patients-with-high-cardiovascular-risk.html
#Roche #Alnylam #Enter #RNAi #Therapeutic #Partnership